Cytori Therapeutics (CYTX) announced Monday that it received a CE Mark in Europe for its secondary reagent Intravase, which coupled with its Celution System is used in the treatment of patients with refractory heart failure due to chronic myocardial ischemia.
Marc Hedrick, President of Cytori Therapeutics stated, "This approval is expected to contribute to revenue growth in 2013 and expands our market access for our cell therapy platform to include intravascular applications. Furthermore, CE Mark approval of Intravase will allow independent European investigators to conduct their own vascular studies."
The company added that the reagent was currently being used in both its refractory heart failure trial or ATHENA in the United States and in the ADVANCE trial for acute heart attack patients in Europe.
For comments and feedback: editorial@rttnews.com